Table 1

Summary of patientscharacteristics
Items Group 1 (n=35) Group 2 (n=20)
Age 68.5 ± 8.2 71.0 ± 8.2
Gender (male/female) 28/7 14/6
Body mass index 24.3 ± 3.2 24.6 ± 3.5
Background (HBV/HCV/Alcohol/NASH/PBC/AIH) 12/14/6/3/1/0 4/11/3/1/0/1
Child-Pugh score (5/6/7/8/9) 20/7/6/0/2 11/5/3/0/1
TNM stage (I/II/III/IV) 18/9/3/5 6/5/4/5
Treatment (RFA/TACE/TOCE/HAIC/Sorafenib/No) 8/6/3/11/1/6 4/6/3/7/0/0
BCAA supplementation (+/−) 21/14 11/9
PT-INR on admission 1.12 ± 0.09 1.09 ± 0.08

HBV hepatitis B virus, HCV hepatitis C virus, NASH nonalcoholic steatohepatitis, PBC primary biliary cirrhosis, AIH autoimmune hepatitis, TNM tumor-node-metastasis, RFA radiofrequency ablation, TACE transcatheter hepatic arterial chemoembolization, TOCE transcatheter oily chemoembolization, HAIC hepatic arterial infusion chemotherapy, BCAA branched-chain amino acids, PT-INR prothrombin time-international normalized ratio.

Yamada et al.

Yamada et al. Nutrition Journal 2013 12:79   doi:10.1186/1475-2891-12-79

Open Data